Level 2

Vectura's Breezhalers see solid third quarter sales

By Josh White

Date: Tuesday 24 Oct 2017

Vectura's Breezhalers see solid third quarter sales

(ShareCast News) - Inhaled airways product device and formulation business Vectura Group confirmed on Tuesday that Novartis Pharma had reported third quarter net sales of $101m for 'Ultibro Breezhaler' and $37m for Seebri Breezhaler.
The FTSE 250 firm said total reported net sales for Ultibro grew 6%, impacted by short term normalisation of stocking effects in certain territories outside Europe.

In Europe, which accounted for the majority of reported net sales, Ultibro grew 18% year-on-year.

Total Seebri net sales were in line with the comparative prior year quarter, as the board expected.

The Vectura board confirmed its continued growth expectations for Ultibro's long term sales potential and outlook for recurring revenue generation for the group.

"Ultibro remains the leading LAMA/LABA with greater than 50% share of total class sales outside the United States," said Vectura chief executive James Ward-Lilley.

"The growth of the class and Ultibro's differentiated profile are reflected in its continued progression particularly in Europe."

Ward-Lilley said net sales in Europe were growing "strongly" despite increasing competition, underpinned by notable performances in Germany and France.

"With strong growth in Europe, along with the recent US launches of Utibron Neohaler and Seebri Neohaler in the US by Sunovion, we remain confident in the outlook and future revenue generation for Vectura from these products."


Email this article to a friend

or share it with one of these popular networks:

Top of Page